Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis.
Bernard G CombeProton RahmanHideto KamedaJuan D CañeteGaia GalloNoah AgadaWen XuMark C GenovesePublished in: Arthritis research & therapy (2020)
SPIRIT-P1 (NCT01695239; Registered August 08, 2012), SPIRIT-P2 (NCT02349295; September 23, 2014), and SPIRIT-P3 (NCT02584855; August 04, 2015).
Keyphrases